MercoPress, en Español
Montevideo, January 13th 2026 - 14:29 UTC
Brazil's Health Regulatory Agency (Anvisa) approved on Monday the use of the drug Sunlenca (lenacapavir) for HIV-1 prevention as pre-exposure prophylaxis (PrEP), Agencia Brasil reported. Read full article
No comments for this story
Please log in or register (it’s free!) to comment. Login with Facebook
Get our news on your inbox! Suscribe
Comments
Disclaimer & comment rulesNo comments for this story
Please log in or register (it’s free!) to comment. Login with Facebook